Unicycive resubmits OLC NDA, expects FDA acceptance within 30 days
AI Summary- Unicycive resubmitted its OLC New Drug Application to the FDA.
- 30 days is the company’s expected timeframe for FDA acceptance.
- FDA cited manufacturing deficiencies in June 2026, not clinical efficacy or safety concerns.